{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "Pfizer, one of the three companies behind the drug, said it did not improve either cognition or daily functioning compared to a placebo.", "headline": {"seo": "Alzheimer\u2019s Drug Fails Its First Big Clinical Trial", "main": "Alzheimer\u2019s Drug Fails Its First Big Clinical Trial", "print_headline": "Alzheimer\u2019s Drug Fails First Big Clinical Trial"}, "abstract": "Pfizer announces that the closely watched experimental Alzheimer's disease treatment bapineuzumab proved ineffective in its first large clinical trial; drug was not found to improve cognition or daily functioning of patients compared to a placebo in the Phase 3 trial; disappointing results deal a blow to the field, to a theory about the cause of the disease and to the three companies behind the drug.", "print_page": "4", "word_count": "634", "_id": "515b47c6fdc59278db0074df", "snippet": "Pfizer, one of the three companies behind the drug, said it did not improve either cognition or daily functioning compared to a placebo.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/07/24/business/alzheimers-drug-fails-its-first-clinical-trial.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Alzheimer's Disease", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Clinical Trials", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Pfizer Inc", "is_major": "Y", "rank": "4", "name": "organizations"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2012-07-24T00:00:00Z", "section_name": "Business Day"}], "meta": {"hits": 1, "offset": 0, "time": 24}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}